Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1976 2
1981 1
1982 1
1983 2
1984 2
1986 2
1987 1
1988 1
1989 3
1990 5
1991 3
1992 5
1993 1
1994 3
1995 4
1996 2
1997 7
1998 2
1999 10
2000 4
2001 9
2002 11
2003 9
2004 14
2005 7
2006 16
2007 9
2008 18
2009 16
2010 19
2011 15
2012 14
2013 27
2014 21
2015 21
2016 29
2017 27
2018 27
2019 24
2020 35
2021 36
2022 31
2023 26
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

486 results

Results by year

Filters applied: . Clear all
Page 1
Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
GBD 2019 Diseases and Injuries Collaborators. GBD 2019 Diseases and Injuries Collaborators. Lancet. 2020 Oct 17;396(10258):1204-1222. doi: 10.1016/S0140-6736(20)30925-9. Lancet. 2020. PMID: 33069326 Free PMC article.
With a rapidly ageing global population, the demands on health services to deal with disabling outcomes, which increase with age, will require policy makers to anticipate these changes. The mix of universal and more geographically specific influences on health reinforces t …
With a rapidly ageing global population, the demands on health services to deal with disabling outcomes, which increase with age, will …
Mitochondrial diseases.
Gorman GS, Chinnery PF, DiMauro S, Hirano M, Koga Y, McFarland R, Suomalainen A, Thorburn DR, Zeviani M, Turnbull DM. Gorman GS, et al. Nat Rev Dis Primers. 2016 Oct 20;2:16080. doi: 10.1038/nrdp.2016.80. Nat Rev Dis Primers. 2016. PMID: 27775730 Review.
Recent advances in in vitro fertilization techniques, including mitochondrial donation, will offer a better reproductive choice for these women in the future. ...
Recent advances in in vitro fertilization techniques, including mitochondrial donation, will offer a better reproductive choice for t …
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, Germino R, Menon S, Sun Y, Wang C, Shapiro AB, Kanik KS, Connell CA; ORAL Surveillance Investigators. Ytterberg SR, et al. N Engl J Med. 2022 Jan 27;386(4):316-326. doi: 10.1056/NEJMoa2109927. N Engl J Med. 2022. PMID: 35081280 Clinical Trial.
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Marso SP, et al. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. N Engl J Med. 2016. PMID: 27295427 Free PMC article. Clinical Trial.
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future.
McGranahan N, Swanton C. McGranahan N, et al. Cell. 2017 Feb 9;168(4):613-628. doi: 10.1016/j.cell.2017.01.018. Cell. 2017. PMID: 28187284 Free article. Review.
We suggest that bold approaches to drug development, harnessing the adaptive properties of the immune-microenvironment while limiting those of the tumor, combined with advances in clinical trial-design, will improve patient outcome....
We suggest that bold approaches to drug development, harnessing the adaptive properties of the immune-microenvironment while limiting those …
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA.
Abbosh C, Frankell AM, Harrison T, Kisistok J, Garnett A, Johnson L, Veeriah S, Moreau M, Chesh A, Chaunzwa TL, Weiss J, Schroeder MR, Ward S, Grigoriadis K, Shahpurwalla A, Litchfield K, Puttick C, Biswas D, Karasaki T, Black JRM, Martínez-Ruiz C, Bakir MA, Pich O, Watkins TBK, Lim EL, Huebner A, Moore DA, Godin-Heymann N, L'Hernault A, Bye H, Odell A, Roberts P, Gomes F, Patel AJ, Manzano E, Hiley CT, Carey N, Riley J, Cook DE, Hodgson D, Stetson D, Barrett JC, Kortlever RM, Evan GI, Hackshaw A, Daber RD, Shaw JA, Aerts HJWL, Licon A, Stahl J, Jamal-Hanjani M; TRACERx Consortium; Birkbak NJ, McGranahan N, Swanton C. Abbosh C, et al. Nature. 2023 Apr;616(7957):553-562. doi: 10.1038/s41586-023-05776-4. Epub 2023 Apr 13. Nature. 2023. PMID: 37055640 Free PMC article.
By measuring subclone cancer cell fractions in preoperative plasma, we found that subclones seeding future metastases were significantly more expanded compared with non-metastatic subclones. Our findings will support (neo)adjuvant trial advances and provide insights into t …
By measuring subclone cancer cell fractions in preoperative plasma, we found that subclones seeding future metastases were significantly mor …
The eIF2α kinases: their structures and functions.
Donnelly N, Gorman AM, Gupta S, Samali A. Donnelly N, et al. Cell Mol Life Sci. 2013 Oct;70(19):3493-511. doi: 10.1007/s00018-012-1252-6. Epub 2013 Jan 26. Cell Mol Life Sci. 2013. PMID: 23354059 Review.
Thus, while significant sequence similarity exists between the eIF2alpha kinases in their kinase domains, underlying their common role in phosphorylating eIF2alpha, additional unique features determine the regulation of these four proteins, that is, what signals activate them. Th …
Thus, while significant sequence similarity exists between the eIF2alpha kinases in their kinase domains, underlying their common role in ph …
Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update.
Bhatnagar N, Nizery L, Tunstall O, Vyas P, Roberts I. Bhatnagar N, et al. Curr Hematol Malig Rep. 2016 Oct;11(5):333-41. doi: 10.1007/s11899-016-0338-x. Curr Hematol Malig Rep. 2016. PMID: 27510823 Free PMC article. Review.
While the majority of cases of TAM undergo spontaneous remission, 10 % will progress to ML-DS by acquiring transforming mutations in additional oncogenes. ...
While the majority of cases of TAM undergo spontaneous remission, 10 % will progress to ML-DS by acquiring transforming mutations in …
Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity.
Copland M. Copland M. Br J Haematol. 2022 Dec;199(5):665-678. doi: 10.1111/bjh.18370. Epub 2022 Jul 22. Br J Haematol. 2022. PMID: 35866251 Free PMC article. Review.
Similar advances in therapy are urgently needed to improve patient outcomes; however, this is challenging given the rarity and heterogeneity of BP-CML, leading to difficulty in designing and recruiting to prospective clinical trials. This review will explore the treatment …
Similar advances in therapy are urgently needed to improve patient outcomes; however, this is challenging given the rarity and heterogeneity …
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers.
Li BT, Michelini F, Misale S, Cocco E, Baldino L, Cai Y, Shifman S, Tu HY, Myers ML, Xu C, Mattar M, Khodos I, Little M, Qeriqi B, Weitsman G, Wilhem CJ, Lalani AS, Diala I, Freedman RA, Lin NU, Solit DB, Berger MF, Barber PR, Ng T, Offin M, Isbell JM, Jones DR, Yu HA, Thyparambil S, Liao WL, Bhalkikar A, Cecchi F, Hyman DM, Lewis JS, Buonocore DJ, Ho AL, Makker V, Reis-Filho JS, Razavi P, Arcila ME, Kris MG, Poirier JT, Shen R, Tsurutani J, Ulaner GA, de Stanchina E, Rosen N, Rudin CM, Scaltriti M. Li BT, et al. Cancer Discov. 2020 May;10(5):674-687. doi: 10.1158/2159-8290.CD-20-0215. Epub 2020 Mar 25. Cancer Discov. 2020. PMID: 32213539 Free PMC article.
486 results